Clinical perspective
Conference Insider Editorial Team / October 22, 2026
Molecular testing plays an increasingly important role in guiding treatment decisions for patients with metastatic breast cancer, particularly when resistance to endocrine therapy develops. Mutations in the ESR1 gene can contribute to reduced sensitivity to certain endocrine treatments, making their detection clinically relevant. A study examining the diagnostic utility of liquid biopsy explored how circulating cell-free DNA (cfDNA) testing can identify ESR1 mutations and other genomic alterations in routine clinical practice.
Read article
Clinical perspective
Conference Insider Editorial Team / October 22, 2026
Understanding how clinical history and tumor genetics influence treatment outcomes is increasingly important in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. ESR1 mutations are a recognized mechanism of resistance to endocrine therapy, creating challenges for treatment selection following disease progression. A large real-world study examined outcomes among patients receiving elacestrant, with particular attention to prior treatment exposure and genomic characteristics that may help inform individualized treatment decisions.
Read article
Clinical perspective
Conference Insider Editorial Team / October 22, 2026
Identifying ESR1 mutations has become increasingly important in the management of estrogen receptor-positive (ER+)/HER2-negative metastatic breast cancer, particularly as endocrine resistance develops during treatment. Although these mutations are relatively uncommon at the start of first-line therapy, their prevalence may increase with continued exposure to endocrine treatment. A recent U.S. real-world study examined ESR1 testing practices and mutation detection patterns to better understand when these molecular changes emerge and how testing is being incorporated into clinical care.
Read article
